NCT07222800 2026-04-21
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Pfizer
Phase 3 Recruiting
Clinical Trials
23 trialsNCT06997497 2026-04-20
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07284849 2026-04-16
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
Incyte Corporation
Phase 3 Recruiting
NCT00217737 2026-04-13
Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT04607421 2025-08-14
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Pfizer
Phase 3 Active not recruiting
NCT05482516 2025-05-22
MRD-GI
Georgetown University
Phase 3 Recruiting
NCT01167725 2024-12-27
Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01606098 2023-09-13
CAIRO4
Dutch Colorectal Cancer Group
Phase 3 Completed
NCT00265850 2020-05-07
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Completed
NCT00544700 2020-02-20
Bevacizumab in Treating Patients Who Have Undergone First-Line Therapy for Metastatic Colorectal Cancer
Swiss Cancer Institute
Phase 3 Terminated
NCT00096278 2019-07-30
Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00911170 2017-12-29
PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study
Amgen
Phase 3 Completed
NCT01279681 2017-12-08
Combination Chemotherapy Plus Bevacizumab With or Without Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00265824 2015-12-11
DREAM
GERCOR - Multidisciplinary Oncology Cooperative Group
Phase 3 Completed
NCT00719797 2015-03-11
TRIBE
Gruppo Oncologico del Nord-Ovest
Phase 3 Completed
NCT00720512 2015-03-11
BEBYP
Gruppo Oncologico del Nord-Ovest
Phase 3 Terminated
NCT00499369 2014-07-31
Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00062426 2013-11-06
Oxaliplatin and Bevacizumab (Avastinâ„¢) With Either Fluorouracil and Leucovorin or Capecitabine in Treating Patients With Advanced Colorectal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00112918 2013-08-27
Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00797485 2013-08-26
Bevacizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Metastatic Colorectal Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00070122 2013-01-25
Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Phase 3 Terminated
NCT00025337 2013-01-24
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
National Cancer Institute (NCI)
Phase 3 Completed
NCT00337389 2007-11-19
Phase III Randomized Study of 5-FU, CoFactor, and Avastin vs. 5-FU, LV and Avastin for First-Line Colorectal Cancer.
Mast Therapeutics, Inc.
Phase 3 Unknown